Esperion Therapeutics
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Esperion Therapeutics sits in the top decile of US sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count).
Esperion Therapeutics: 23 sponsored US clinical trials, 1 recruiting.
Esperion Therapeutics sponsors 23 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 22 completed. 8 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Hypercholesterolemia, with 4 trials.
Top-decile sponsor footprint
Esperion Therapeutics ranks in the top decile of sponsors by registered trial count (#668 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
22 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
23 total, page 1 of 1
Bempedoic Acid Pregnancy Surveillance Program
NCT05103254
Milk-Only Lactation Study to Evaluate the Concentration of Bempedoic Acid and Bempedoic Acid/Ezetimibe Fixed Combination Drug Product (FCDP) in the Breast Milk of Healthy Lactating Women
NCT06021951
A Clinical Study in Children With Heterozygous Familial Hypercholesterolemia (HeFH) Aged 6 to 17 Treated Once Daily With Bempedoic Acid Oral Dosing (CLEAR Path 1)
NCT05694260
Bempedoic Acid + Ezetimibe Fixed-Dose Combination (FDC) Study in Patients With Type 2 Diabetes and Elevated LDL-C
NCT03531905
A Study Evaluating the Safety and Efficacy of Bempedoic Acid Plus Ezetimibe Fixed-Dose Combination Compared to Bempedoic Acid, Ezetimibe, and Placebo in Patients Treated With Maximally Tolerated Statin Therapy
NCT03337308
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg When Added to PCSK9 Inhibitor Therapy
NCT03193047
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
NCT03067441
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) 180mg, Ezetimibe 10mg, and Atorvastatin 20 mg Triplet Therapy in Patients With Elevated LDL-C
NCT03051100
Evaluation of Major Cardiovascular Events in Participants With, or at High Risk for, Cardiovascular Disease Who Are Statin Intolerant Treated With Bempedoic Acid (ETC-1002) or Placebo
NCT02993406
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) as Add-on to Ezetimibe Therapy in Patients With Elevated LDL-C (CLEAR Tranquility)
NCT03001076
Evaluation of Long-Term Efficacy of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia at High Cardiovascular Risk
NCT02991118
Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
NCT02988115
Evaluation of Long-Term Safety and Tolerability of ETC-1002 in High-Risk Patients With Hyperlipidemia and High CV Risk (CLEAR Harmony)
NCT02666664
A Study Of Pharmacokinetics, Pharmacodynamics And Safety Of Adding ETC-1002 To Atorvastatin 80 mg
NCT02659397
Evaluation of ETC-1002 in Participants With Hypercholesterolemia and Hypertension
NCT02178098
Evaluation of ETC-1002 vs Placebo in Patients Receiving Ongoing Statin Therapy
NCT02072161
Evaluation of ETC-1002, Ezetimibe, and the Combination in Hypercholesterolemic Patients
NCT01941836
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
NCT01779453
A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
NCT01751984
A Single Center Study to Evaluate the Efficacy and Safety of ETC 1002 in Subjects With Type 2 Diabetes
NCT01607294
A Multiple Ascending Dose Study of ETC-1002 in Healthy Subjects
NCT01485146
A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
NCT01262638
A Multiple Ascending Dose Study of ETC-1002 in Subjects With Mild Dyslipidemia
NCT01105598
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 12 |
| Phase 3 | 7 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the Esperion Therapeutics pipeline
1 recruiting of 23 indexed (4% open); 22 completed (96%).
Phase mix: 8 late (III/IV) vs 14 early (I/II) (early-phase heavy).
Top condition: Hypercholesterolemia (4 trials), 5 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Esperion Therapeutics: open-pipeline peers nationwide
Peers matched on 23 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Esperion Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 23 trials (± recruiting share)
- AMAG Pharmaceuticals · 23 trials · 9% recruiting
- AtriCure · 23 trials · 22% recruiting
- Cara Therapeutics · 23 trials · 0% recruiting
- Craig L Slingluff, Jr · 23 trials · 4% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Tonix Pharmaceuticals · 4% recruiting · 23 trials
- Rockefeller University · 4% recruiting · 117 trials
- Galderma R&D · 4% recruiting · 158 trials
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · 4% recruiting · 45 trials
Related
What to do with this Esperion Therapeutics page
23 registered trials is a research-attention snapshot, not an endorsement of Esperion Therapeutics or any single study.
- 1 of Esperion Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Hypercholesterolemia is the condition Esperion Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Hypercholesterolemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Esperion Therapeutics pipeline card: 23 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.